REDWOOD CITY, Calif.,
May 6, 2015 /PRNewswire/
-- Genomic Health, Inc. (Nasdaq: GHDX) today announced that
Kim Popovits, Chairman of the Board, Chief Executive Officer &
President, will present at the Bank of America Merrill Lynch 2015
Healthcare Conference in Las Vegas
on Tuesday, May 12 at 3:40 p.m. Pacific Time (PT).
To access the live and subsequently archived webcast of the
presentation, go to the Investor Relations section of the
company's web site at
http://investor.genomichealth.com. Please connect to the web
site at least 15 minutes prior to the call to allow for any
software download that may be necessary.
About Genomic Health
Genomic Health, Inc. (Nasdaq:
GHDX) is the world's leading provider of genomic-based diagnostic
tests that address both the overtreatment and optimal treatment of
early-stage cancer, one of the greatest issues in healthcare today.
The company is applying its world-class scientific and commercial
expertise and infrastructure to lead the translation of massive
amounts of genomic data into clinically-actionable results for
treatment planning throughout the cancer patient's journey, from
diagnosis to treatment selection and monitoring. The company is
based in Redwood City, California,
with European headquarters in Geneva,
Switzerland. For more information, please visit,
www.GenomicHealth.com and follow the company on Twitter:
@GenomicHealth, Facebook, YouTube and LinkedIn.
About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer
tests applies advanced genomic science to reveal the unique biology
of a tumor in order to optimize cancer treatment decisions.
The company's flagship product, the Oncotype DX breast
cancer test, has been shown to predict the likelihood of
chemotherapy benefit as well as recurrence in invasive breast
cancer. Additionally, the test predicts the likelihood of
recurrence in a pre-invasive form of breast cancer
called DCIS. With half a million patients tested in more
than 80 countries, the Oncotype DX tests have redefined
personalized medicine by making genomics a critical part of cancer
diagnosis and treatment. To learn more about Oncotype DX
breast cancer tests,
visit: www.OncotypeDX.com or www.mybreastcancertreatment.org.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the belief benefits and
attributes of the company's tests. Forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially, and reported results should not be considered
as an indication of future performance. These risks and
uncertainties include, but are not limited to: the risks and
uncertainties associated with the regulation of the company's
tests; the results of clinical studies; the applicability of
clinical study results to actual outcomes; our ability to develop
and commercialize new tests and expand into new markets
domestically and internationally; the risk that the company may not
obtain or maintain sufficient levels of reimbursement, domestically
or abroad, for its existing tests and any future tests it may
develop; the risks of competition; unanticipated costs or delays in
research and development efforts; the company's ability to obtain
capital when needed and the other risks set forth in the company's
filings with the Securities and Exchange Commission, including
the risks set forth in the company's annual report on Form 10-K for
the year ended December 31, 2014. These forward-looking
statements speak only as of the date hereof. Genomic
Health disclaims any obligation to update these
forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype
DX, Recurrence Score, and DCIS Score are trademarks or registered
trademarks of Genomic Health, Inc. All other trademarks
and service marks are the property of their respective
owners.
Logo -
http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genomic-health-to-present-at-the-bank-of-america-merrill-lynch-2015-healthcare-conference-300077282.html
SOURCE Genomic Health, Inc.